BeOne Medicines Ltd
262 hedge funds and large institutions have $15B invested in BeOne Medicines Ltd in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 83 increasing their positions, 90 reducing their positions, and 34 closing their positions.
35% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 34
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
4% more funds holding
Funds holding: 253 → 262 (+9)
0.5% less ownership
Funds ownership: 4.67% → 4.17% (-0.5%)
8% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 90
26% less capital invested
Capital invested by funds: $20.4B → $15B (-$5.35B)
77% less call options, than puts
Call options by funds: $28.3M | Put options by funds: $125M
Top Buyers
Top Sellers
ONC Hedge Fund Activity: Q4 2021 in Review
262 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q4 2021, worth a combined $15B — down 26% from $20.4B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ONC positions and 34 closed out — a net gain of 12 holders — while 83 added to existing stakes and 90 trimmed.
The largest buyer was Indus Capital Partners, adding an estimated $30.4M. The largest seller was Boxer Capital, cutting an estimated $89.2M.
- 262 institutional investors held BeOne Medicines Ltd (ONC) as of Q4 2021, up from 253 in Q3 2021.
- Funds reported $15B of BeOne Medicines Ltd stock for Q4 2021, down 26% quarter-over-quarter.
- 46 funds opened new BeOne Medicines Ltd positions in Q4 2021 and 34 closed out, a net change of +12 holders.
- The largest BeOne Medicines Ltd buyer in Q4 2021 was Indus Capital Partners, an estimated $30.4M added.
- The largest BeOne Medicines Ltd seller in Q4 2021 was Boxer Capital, an estimated $89.2M sold.
Based on aggregated 13F filings for Q4 2021.